Next Article in Journal / Special Issue
Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives
Previous Article in Journal
Metabolite Profiles of Male and Female Humboldt Penguins
Previous Article in Special Issue
Beta Adrenergic Signaling: A Targetable Regulator of Angiosarcoma and Hemangiosarcoma
Article Menu

Export Article

Open AccessReview
Vet. Sci. 2015, 2(4), 363-387; doi:10.3390/vetsci2040363

Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure

1
DVM/PhD Combined Degree and Comparative Molecular Biosciences Graduate Programs, Department of Veterinary Clinical Sciences, College of Veterinary Medicine and Animal Cancer Care and Research Center, University of Minnesota, St. Paul, MN 55108, USA
2
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Animal Cancer Care and Research Center, Center for Immunology, Masonic Cancer Center, and Stem Cell Institute, University of Minnesota, Minneapolis, MN 55108, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Duncan C. Ferguson and Margarethe Hoenig
Received: 20 August 2015 / Revised: 5 October 2015 / Accepted: 13 October 2015 / Published: 19 October 2015
(This article belongs to the Special Issue Comparative Pathogenesis of Cancers in Animals and Humans)
View Full-Text   |   Download PDF [904 KB, uploaded 19 October 2015]   |  

Abstract

Harnessing the ability of the immune system to eradicate cancer has been a long-held goal of oncology. Work from the last two decades has finally brought immunotherapy into the forefront for cancer treatment, with demonstrable clinical success for aggressive tumors where other therapies had failed. In this review, we will discuss a range of therapies that are in different stages of clinical or preclinical development for companion animals with cancer, and which share the common objective of eliciting adaptive, anti-tumor immune responses. Even though challenges remain, manipulating the immune system holds significant promise to create durable responses and improve outcomes in companion animals with cancer. Furthermore, what we learn from this process will inform and accelerate development of comparable therapies for human cancer patients. View Full-Text
Keywords: adaptive immunity; T-lymphocytes; antibodies; immunization; Fas ligand; virotherapy adaptive immunity; T-lymphocytes; antibodies; immunization; Fas ligand; virotherapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Anderson, K.L.; Modiano, J.F. Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure. Vet. Sci. 2015, 2, 363-387.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vet. Sci. EISSN 2306-7381 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top